JP2019526580A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526580A5 JP2019526580A5 JP2019512191A JP2019512191A JP2019526580A5 JP 2019526580 A5 JP2019526580 A5 JP 2019526580A5 JP 2019512191 A JP2019512191 A JP 2019512191A JP 2019512191 A JP2019512191 A JP 2019512191A JP 2019526580 A5 JP2019526580 A5 JP 2019526580A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- seq
- administered
- weeks
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims description 74
- 239000013598 vector Substances 0.000 claims description 55
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 238000011225 antiretroviral therapy Methods 0.000 claims description 20
- 230000002163 immunogen Effects 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010000807 Acute HIV infection Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 241001212582 Ancara Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383140P | 2016-09-02 | 2016-09-02 | |
| US62/383,140 | 2016-09-02 | ||
| PCT/US2017/049817 WO2018045267A1 (en) | 2016-09-02 | 2017-09-01 | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526580A JP2019526580A (ja) | 2019-09-19 |
| JP2019526580A5 true JP2019526580A5 (enExample) | 2020-10-15 |
Family
ID=59887395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512191A Pending JP2019526580A (ja) | 2016-09-02 | 2017-09-01 | 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10307477B2 (enExample) |
| EP (1) | EP3506937A1 (enExample) |
| JP (1) | JP2019526580A (enExample) |
| CN (1) | CN110494159A (enExample) |
| AU (1) | AU2017318689A1 (enExample) |
| CA (1) | CA3035759A1 (enExample) |
| WO (1) | WO2018045267A1 (enExample) |
| ZA (1) | ZA201901899B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101971808B1 (ko) * | 2014-09-26 | 2019-04-23 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물 |
| HUE045993T2 (hu) | 2015-12-15 | 2020-01-28 | Janssen Vaccines & Prevention Bv | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások |
| MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| EP3747463A1 (en) | 2016-09-15 | 2020-12-09 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
| US11229693B2 (en) | 2017-06-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding HIV antigens, and methods of use thereof |
| EP3655032A1 (en) | 2017-07-19 | 2020-05-27 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
| WO2019055888A1 (en) * | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020234839A1 (en) * | 2019-05-22 | 2020-11-26 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| TW202110476A (zh) * | 2019-05-22 | 2021-03-16 | 荷蘭商傑森疫苗防護公司 | 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法 |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| WO2022272275A1 (en) * | 2021-06-25 | 2022-12-29 | Janssen Vaccines & Prevention B.V. | Combinations of vaccines and neutralizing antibodies for treating human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2024036217A2 (en) * | 2022-08-09 | 2024-02-15 | Fred Hutchinson Cancer Center | Immunization strategies to more naturally guide the maturation of antibodies against human immunodeficiency virus (hiv) in hiv-infected subjects |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| WO2001019958A2 (en) | 1999-09-17 | 2001-03-22 | Dana-Farber Cancer Institute, Inc. | Stabilized soluble glycoprotein trimers |
| CA2421151C (en) | 2000-11-23 | 2013-07-02 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| ES2416629T3 (es) | 2002-12-03 | 2013-08-02 | University Of Massachusetts | Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación |
| EP1610816B1 (en) | 2003-03-28 | 2013-01-02 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mva virus expressing modified hiv envelope, gag, and pol genes |
| CA2539021A1 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
| WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
| US20080274134A1 (en) | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
| CA2573702C (en) | 2004-07-16 | 2013-10-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| CA2656741A1 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| CA2620874A1 (en) | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Polyvalent vaccine |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| CA2655934A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CA2667358A1 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| US9017691B2 (en) | 2008-11-18 | 2015-04-28 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| WO2011082087A2 (en) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Dps fusion proteins for use in vaccines and diagnostics |
| CA2786333C (en) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
| CA3109036C (en) | 2010-08-31 | 2023-08-01 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| SG11201503864TA (en) | 2012-11-16 | 2015-06-29 | Beth Israel Hospital | Recombinant adenoviruses and use thereof |
| EP2983686B1 (en) | 2013-01-07 | 2024-05-29 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| EP3052132B1 (en) | 2013-09-30 | 2020-07-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| AU2015222153A1 (en) * | 2014-02-28 | 2016-09-01 | Beth Israel Deaconess Medical Center Inc. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| WO2016037154A1 (en) | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
| KR101971808B1 (ko) * | 2014-09-26 | 2019-04-23 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물 |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| HUE045993T2 (hu) | 2015-12-15 | 2020-01-28 | Janssen Vaccines & Prevention Bv | Emberi immunhiány vírus antigének, vektorok, készítmények és alkalmazásukra szolgáló eljárások |
| MA45381A (fr) | 2016-06-16 | 2021-04-21 | Janssen Vaccines & Prevention Bv | Formulation de vaccin contre le vih |
| AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| EP3747463A1 (en) | 2016-09-15 | 2020-12-09 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
-
2017
- 2017-09-01 AU AU2017318689A patent/AU2017318689A1/en not_active Abandoned
- 2017-09-01 US US15/693,650 patent/US10307477B2/en active Active
- 2017-09-01 WO PCT/US2017/049817 patent/WO2018045267A1/en not_active Ceased
- 2017-09-01 EP EP17768310.9A patent/EP3506937A1/en not_active Ceased
- 2017-09-01 CN CN201780067261.7A patent/CN110494159A/zh active Pending
- 2017-09-01 JP JP2019512191A patent/JP2019526580A/ja active Pending
- 2017-09-01 CA CA3035759A patent/CA3035759A1/en active Pending
-
2019
- 2019-03-27 ZA ZA2019/01899A patent/ZA201901899B/en unknown
- 2019-04-16 US US16/385,062 patent/US10525123B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526580A5 (enExample) | ||
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| Ertl et al. | Novel vaccine approaches. | |
| Hasanpourghadi et al. | COVID-19 vaccines based on adenovirus vectors | |
| Bailey | An assessment of the role of chimpanzees in AIDS vaccine research | |
| JP2017515508A5 (enExample) | ||
| JP2019123734A (ja) | 免疫応答の増進を目的とする方法及び組成物 | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| JP2019505560A5 (enExample) | ||
| WO2020247547A1 (en) | Cancer vaccine compositions and methods for use thereof | |
| JP2016074727A5 (enExample) | ||
| CA2764903C (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| WO2002068654A2 (es) | Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana | |
| US11274282B2 (en) | Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen | |
| Kaulfuß et al. | Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery | |
| JP4989224B2 (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| JP2017534284A (ja) | 最適化ＨＩＶ遺伝子を含有及び発現する遺伝的に安定な複製可能センダイ（Ｓｅｎｄａｉ）ウイルスベクター | |
| US20150359877A1 (en) | Viral Vaccine Vectors | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| Ngu et al. | Dendritic cell targeted HIV‐1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8+ T cells | |
| JP7314441B2 (ja) | 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原 | |
| CN101394868A (zh) | 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 | |
| Hanke | Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses | |
| JP7454320B2 (ja) | アジュバントとしての腫瘍溶解性ウイルス | |
| US6783762B1 (en) | Product and method for obtaining specific immunization with one or more antigens |